[go: up one dir, main page]

MY170840A - Aqueous composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid - Google Patents

Aqueous composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid

Info

Publication number
MY170840A
MY170840A MYPI2014702590A MYPI2014702590A MY170840A MY 170840 A MY170840 A MY 170840A MY PI2014702590 A MYPI2014702590 A MY PI2014702590A MY PI2014702590 A MYPI2014702590 A MY PI2014702590A MY 170840 A MY170840 A MY 170840A
Authority
MY
Malaysia
Prior art keywords
bromobenzoyl
amino
phenylacetic acid
aqueous composition
composition containing
Prior art date
Application number
MYPI2014702590A
Inventor
Takashi Morimoto
Hiroyuki Asada
Kyohei Takahashi
Tomoyuki Okamoto
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MY170840A publication Critical patent/MY170840A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to an aqueous composition comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a salt thereof, and optionally benzalkonium chloride and/or a polyoxyethylene sorbitan fatty acid ester. By means of restricting the contents of benzalkonium chloride and the polyoxyethylene sorbitan fatty acid ester to within specific ranges, a composition can be obtained in which the stability of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a salt thereof is maintained and there are no changes in appearance.
MYPI2014702590A 2012-03-28 2013-03-28 Aqueous composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid MY170840A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012073181 2012-03-28

Publications (1)

Publication Number Publication Date
MY170840A true MY170840A (en) 2019-09-10

Family

ID=49260248

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014702590A MY170840A (en) 2012-03-28 2013-03-28 Aqueous composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid

Country Status (9)

Country Link
JP (1) JP5922609B2 (en)
KR (1) KR20140139501A (en)
CN (1) CN104203224A (en)
IN (1) IN2014DN07767A (en)
MY (1) MY170840A (en)
PH (1) PH12014502171A1 (en)
SG (1) SG11201405837YA (en)
TW (1) TWI604858B (en)
WO (1) WO2013147000A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180016469A (en) * 2015-06-10 2018-02-14 산텐 세이야꾸 가부시키가이샤 Eye drops, and eye drops preservative efficacy methods
KR20200099547A (en) * 2017-12-14 2020-08-24 산텐 세이야꾸 가부시키가이샤 Eye drops containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or salt thereof
CN114224830A (en) * 2021-12-24 2022-03-25 辰欣药业股份有限公司 Single-dose bacteriostatic-free ophthalmic preparation and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002308764A (en) * 2001-02-09 2002-10-23 Taisho Pharmaceut Co Ltd Ophthalmic pharmaceutical composition
WO2005046700A1 (en) * 2003-11-14 2005-05-26 Senju Pharmaceutical Co., Ltd. Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac
CN1823754A (en) * 2006-03-28 2006-08-30 卢秀莲 Sodium bromophenolate eye drops and its preparation method
CN101313899B (en) * 2007-06-01 2012-02-29 北京德众万全药物技术开发有限公司 Medicament composition for eyes containing sodium bromfenac
RU2010138799A (en) * 2008-02-21 2012-03-27 Иста Фармасьютикалз (Us) OPHTHALMIC NON-STEROID ANTI-INFLAMMATORY AGENTS AS ADJUVENTS
CN101322683B (en) * 2008-07-30 2013-01-16 浙江三叶药业有限公司 Gel for eye containing bromfenac sodium hydrate and preparation thereof
CA2824433C (en) * 2011-01-18 2019-11-12 Senju Pharmaceutical Co., Ltd. Aqueous liquid bromfenac composition having preservative efficacy
JP6012231B2 (en) * 2011-04-08 2016-10-25 ロート製薬株式会社 Bromfenac-containing composition

Also Published As

Publication number Publication date
TWI604858B (en) 2017-11-11
JP5922609B2 (en) 2016-05-24
CN104203224A (en) 2014-12-10
IN2014DN07767A (en) 2015-05-15
PH12014502171A1 (en) 2014-12-10
JP2013227300A (en) 2013-11-07
WO2013147000A1 (en) 2013-10-03
TW201343197A (en) 2013-11-01
KR20140139501A (en) 2014-12-05
SG11201405837YA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
EA201590518A1 (en) STABLE WATER COMPOSITIONS ADALIMUMAB
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
PH12012502138B1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
EA201390081A1 (en) DEUTERED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLOR-1-METHYL-2-OXOHINOLIN-3-CARBOXAMIDE, ITS SALT AND THEIR APPLICATION
PH12013500603A1 (en) Meglumine salt of 6-flouro-3-hydroxy-2-pyrazine carboxamide
UA107865C2 (en) Heterocyclic carboxamides
BR112014028334A2 (en) dipeptide derivatives of lysine glutamic acid.
EA201590617A1 (en) COMPOSITIONS OF ALKYLED CYCLODEXTRIN AND METHODS FOR THEIR PRODUCTION AND APPLICATION
IN2015DN00402A (en)
MX356126B (en) Use of glutamide stabilizers.
MX346678B (en) Immunologically useful arginine salts.
IN2015DN03975A (en)
UA111333C2 (en) Method for producing l-arginine salt of perindropryl
MX364538B (en) Anti-malodor oral care composition.
EA201590708A1 (en) MODIFIED HYALURONIC ACID DERIVATIVES AND THEIR APPLICATION
IN2015DN02668A (en)
MY170840A (en) Aqueous composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid
UA115072C2 (en) Hydantoin derivative
MX341189B (en) Bromfenac aqueous liquid composition having preservative efficiency.
GT201300003A (en) CRYSTAL FORM DELTA OF THE ARGININE SALT OF PERINDOPRILE, ITS PREPARATION PROCEDURE, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EA201691285A1 (en) COMPOSITION FOR HAIR CARE
PL2919755T3 (en) Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
EA201300907A1 (en) METHOD OF FIGHTING PHYTOPATHOGEN MUSHROOMS
MY182059A (en) Pharmaceutical composition for external use
EA201500438A1 (en) CRYSTALLINE PHASE (3S, 3S ') - 4,4'-DISULFANDIIL-BIS- (3-AMINOBUTAN-1-SULFO ACIDS) WITH L-LYSIN